Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Gentofte, Copenhagen | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments.
Furthermore to describe persistence to each OAT and risk of bleeding after initiating each OAT.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient treated with Apixaban | |||
| Patient treated with Rivaroxaban | |||
| Patient treated with Dabigatran | |||
| Patient treated with vitamin K antagonists |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The sociodemographic characteristics of all patients with nonvalvular atrial fibrillation (NVAF) who initiated an OAT based on data available in Danish National Patient Registry | Sociodemographic characteristics: Age,sex, ethnicity, region of residence, education, income and employment status | Approximately 4 years |
| Clinical characteristics of all patients with NVAF who initiated an Oral anticoagulant therapy (OAT) based on data available in Danish National Patient Registry | Clinical characteristics: Myocardial infarction, Stroke, Thromboembolism, Hypertension, Peripheral artery disease, Congestive cardiac failure | Approximately 4 years |
| Previous Oral anticoagulant therapy of all patients with NVAF who initiated an OAT based on data available in Danish National Patient Registry | Oral anticoagulant: Apixaban, Dabigatran, Rivaroxaban and Vitamin K antagonist | Approximately 4 years |
| Concomitant medications of all patients with NVAF who initiated an OAT based on data available in Danish National Patient Registry | Concomitant medication Drug classes: Anti-arrhythmic agents, Antidiabetic agents, Antihypertensive agents, Proton pump inhibitors | Approximately 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| Persistence to each OAT after initiation as monotherapy | Persistence will be defined as treatment discontinuation and will be measured by estimating the following: Discontinuation - the absence of any delivery of this product and of any other anticoagulation therapy of interest for 30 days. The date of discontinuation the OAT will be determined according to predefined algorithms to calculate treatment duration in the national prescription registry. Sensitivity analysis including a 30 and 60 day grace period will be performed to take into account incomplete adherence to treatment and dose modifications |
Not provided
Inclusion Criteria:
The study population will consist of all patients in Denmark who meet the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subject must be over 18 years of age, male and females are eligible
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Hellerup | 2900 | Denmark |
Not provided
Not provided
Not provided
Not provided
| Approximately 4 years |
| Persistence between apixaban and other OAT | Oral anticoagulant: Dabigatran, Rivaroxaban and Vitamin K antagonist | Approximately 4 years |
| Clinically relevant bleeding events after initiating an OAT as monotherapy | Approximately 4 years |
| Bleeding events requiring hospitalization in patients treated with apixaban | Approximately 4 years |
| Bleeding events requiring out-patient care in patients treated with apixaban | Approximately 4 years |
| Bleeding events requiring hospitalization in patients treated with rivaroxaban | Approximately 4 years |
| Bleeding events requiring out-patient care in patients treated with rivaroxaban | Approximately 4 years |